Whole exome sequencing is a powerful genomic technology that focuses on analysing the protein-coding regions of an individual's DNA. Its applications include identifying genetic mutations associated with rare diseases, cancer profiling, and understanding inherited conditions. Analysing specific genes, researchers and clinicians can pinpoint disease-causing variations and tailor precise treatments. With its comprehensive coverage of essential genetic information, whole exome sequencing offers a cost-effective and efficient alternative to whole genome sequencing, making it an invaluable tool for advancing personalized medicine and genetic research.
According to Data Bridge Market Research, the Global Whole Exome Sequencing Market is expected to grow with a CAGR of 19.0% in the forecast period of 2022 to 2029.
“Increased adoption of next-generation sequencing (NGS) technologies boosts the market’s growth”
The whole exome sequencing (WES) market experiences growth due to increased adoption of next-generation sequencing (NGS) technologies. WES enables cost-effective and efficient sequencing of the coding regions of the genome, providing valuable insights into genetic variations and mutations. As NGS becomes more accessible and affordable, researchers and clinicians embrace WES for disease diagnosis, personalized medicine, and genetic research. The growing demand for precision medicine and the understanding of rare diseases drive the WES market's expansion, offering transformative possibilities in healthcare and scientific exploration.
What restraints the growth of the global whole exome sequencing market?
“Less comprehensive coverage of exons restraints the market’s growth”
The growth of the whole exome sequencing (WES) market is restrained by its less comprehensive coverage of exons compared to whole genome sequencing (WGS). While WES is cost-effective and efficient in targeting the coding regions, it misses non-coding regions and regulatory elements that WGS can capture. This limitation may hinder researchers from obtaining a complete understanding of genetic variations and disease-causing mutations. However, ongoing advancements in sequencing technologies and the integration of WES with other omics approaches offer potential solutions to overcome this limitation and further drive market growth.
Segmentation: Global Whole Exome Sequencing Market
The global whole exome sequencing market is segmented on the basis of component, product and service, application, end user, and distribution channel.
- On the basis of component, the global whole exome sequencing market is segmented into second-generation sequencing and third-generation sequencing.
- On the basis of product and service, the global whole exome sequencing market is segmented into systems, kits, and services.
- On the basis of application, the global whole exome sequencing market is segmented into drug discovery and development, agriculture and animal research, diagnostics, personalized medicine and others.
- On the basis of end user, the global n whole exome sequencing market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, clinical laboratories, and others.
- On the basis of distribution channel, the global whole exome sequencing market is segmented into direct trade, retail sales, and others.
Regional Insights: North America dominates the Global Whole Exome Sequencing Market
North America is dominating due to the presence of key market players and a significant consumer market with a high GDP contributing to the growth prospects of the region. The U.S. is expected to experience growth due to continuous technological advancements, particularly in areas such as genomics, data analytics, and healthcare. These factors create a conducive environment for the expansion of various industries and drive economic development.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-whole-exome-sequencing-market
Recent Developments
- In May, 2022, Thermo Fisher Scientific, a global leader in scientific solutions, has partnered with the Qatar Genome Program (QGP), a member of Qatar Foundation (QF), to advance genomic research and clinical applications in Qatar. The collaboration aims to promote predictive genomics and precision medicine across Arab populations worldwide.
- In March, 2022, Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics joined forces to establish the CardioGenomic Testing Alliance (CGTA), focused on promoting genomic testing in cardiology. CGTA aims to raise awareness, educate healthcare providers, and improve clinical outcomes by adhering to existing guidelines from medical societies, ultimately benefiting the companies involved.
The Prominent Key Players Operating in the Global Whole Exome Sequencing Market Include:
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN (Germany)
- Illumina, Inc. (U.S.)
- Beckman Coulter, Inc. (U.S.)
- Eurofins Scientific (Luxembourg)
- BIONEER CORPORATION (South Korea)
- ExoDx (a part of Bio-Techne) (U.S.)
- FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd) (U.S.)
- GeneFirst Limited (U.K.)
- CeGaT GmbH (Germany)
- Meridian (U.S.)
- Merck KGaA (Germany)
- SOPHiA GENETICS (Switzerland)
- Azenta U.S. Inc. (U.S.)
- CD Genomics (U.S.)
- Twist Bioscience (U.S.)
- PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.) (U.S.)
- GeneDx, LLC (U.S.)
- Psomagen (South Korea)
- Integrated DNA Technologies, Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global whole exome sequencing market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Whole Exome Sequencing Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
